141 XNAS Volume
XNAS 21 Mar, 2025 5:30 PM (EDT)
| Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|
| Erik Atkisson | General Counsel and CCO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Mar 2023 | 120,000 | 120,000 | - | - | Stock Option (Right to Buy) | |
| Robert Doebele | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 123,325 | 123,325 | - | - | Stock Option (Right to Buy) | |
| Nelson Cabatuan | VP of Finance & Admin | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 65,325 | 65,325 | - | - | Stock Option (Right to Buy) | |
| Avanish Vellanki | Director, Chairman and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 318,600 | 318,600 | - | - | Stock Option (Right to Buy) | |
| Richard P. Bryce | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 7.80 per share. | 21 Nov 2022 | 45,000 | 928,207 | - | 7.8 | 351,000 | Common Stock |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 8.27 per share. | 21 Nov 2022 | 77,000 | 1,005,207 | - | 8.3 | 636,790 | Common Stock |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 5.83 per share. | 08 Nov 2022 | 42,881 | 883,207 | - | 5.8 | 249,996 | Common Stock |
| Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Jul 2022 | 3,890 | 5,000 | - | - | Stock Option (Right to Buy) | |
| Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 06 Jul 2022 | 3,890 | 476,827 | - | 4.0 | 15,366 | Common Stock |
| Tran B. Nguyen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Gorjan Hrustanovic | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Stefani A. Wolff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Peter Radovich | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Avanish Vellanki | Director, Chairman and CEO, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 2.29 per share. | 01 Jun 2022 | 25,000 | 2,471,627 | - | 2.3 | 57,250 | Common Stock |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jun 2022 | 20,000 | 20,000 | - | - | Stock Option (Right to Buy) | |
| Avanish Vellanki | Director, Chairman and CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Apr 2022 | 59,618 | 2,446,627 | - | 0 | Common Stock | |
| Avanish Vellanki | Director, Chairman and CEO, Ten Percent Owner | Gift of securities by or to the insider at price $ 0.00 per share. | 14 Apr 2022 | 59,618 | 79,283 | - | 0 | Common Stock | |
| Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 13 Apr 2022 | 3,000 | 472,937 | - | 4.0 | 11,850 | Common Stock |
| Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Apr 2022 | 3,000 | 8,890 | - | - | Stock Option (Right to Buy) | |
| Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.95 per share. | 31 Mar 2022 | 2,000 | 469,937 | - | 4.0 | 7,900 | Common Stock |
| Robert Doebele | See Remarks | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Mar 2022 | 2,000 | 11,890 | - | - | Stock Option (Right to Buy) | |
| Avanish Vellanki | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.00 per share. | 11 Mar 2022 | 14,468 | 2,837,009 | - | 4 | 57,872 | Common Stock |
| Avanish Vellanki | Director, President and CEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2022 | 14,468 | 31,832 | - | - | Stock Option (Right to Buy) | |
| Avanish Vellanki | Director, President and CEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2022 | 182,300 | 182,300 | - | - | Stock Option (Right to Buy) | |
| Robert Doebele | EVP, Chief Scientific Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 72,000 | 72,000 | - | - | Stock Option (Right to Buy) | |
| Nelson Cabatuan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 32,000 | 32,000 | - | - | Stock Option (Right to Buy) | |
| Richard P. Bryce | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2022 | 53,064 | 53,064 | - | - | Stock Option (Right to Buy) | |
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 14.30 per share. | 21 Sep 2021 | 3,786 | 840,326 | - | 14.3 | 54,140 | Common Stock |
| Franklin M. Berger | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Stefani A. Wolff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 May 2021 | 24,000 | 24,000 | - | - | Stock Option (Right to Buy) | |
| Nelson Cabatuan | See Remarks | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 May 2021 | 6,000 | 6,000 | - | - | Stock Option (Right to Buy) | |
| Peter Radovich | Director | 27 Apr 2021 | 9,500 | 0 | - | - | Series A Preferred Stock | ||
| Peter Radovich | Director | 27 Apr 2021 | 8,796 | 8,796 | - | - | Common Stock | ||
| Robert Doebele | EVP, Chief Scientific Officer | 27 Apr 2021 | 4,932 | 467,937 | - | - | Common Stock | ||
| Robert Doebele | EVP, Chief Scientific Officer | 27 Apr 2021 | 5,327 | 0 | - | - | Series A Preferred Stock | ||
| Avanish Vellanki | Director, President and CEO | 27 Apr 2021 | 11,212 | 2,372,541 | - | - | Common Stock | ||
| Avanish Vellanki | Director, President and CEO | 27 Apr 2021 | 12,108 | 0 | - | - | Series A Preferred Stock | ||
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 17.00 per share. | 23 Apr 2021 | 120,000 | 120,000 | - | 17 | 2,040,000 | Common Stock |
| Franklin M. Berger | Director | 23 Apr 2021 | 578,397 | 0 | - | - | Series B Preferred Stock | ||
| Franklin M. Berger | Director | 23 Apr 2021 | 189,998 | 0 | - | - | Series A Preferred Stock | ||
| Franklin M. Berger | Director | 23 Apr 2021 | 535,601 | 836,540 | - | - | Common Stock | ||
| Franklin M. Berger | Director | 23 Apr 2021 | 175,939 | 300,939 | - | - | Common Stock | ||
| Franklin M. Berger | Director | Purchase of securities on an exchange or from another person at price $ 15.78 per share. | 23 Apr 2021 | 5,000 | 125,000 | - | 15.8 | 78,900 | Common Stock |